已收盘 12-19 16:00:00 美东时间
+1.225
+5.69%
DBV Technologies reports positive Phase 3 data for its VIASKIN Peanut patch in children, supporting a planned U.S. BLA filing in 2026.
12-17 21:49
DBV Technologies' 2025 Combined General Meeting held on June 11, 2025, in Châtillon, France, resulted in shareholders approving all proposed resolutions. The company, focused on developing treatments for food allergies using its Viaskin™ platform, continues clinical trials for peanut allergies in toddlers and children.
06-11 20:30
JMP Securities analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:DBVT) with a Market Outperform and maintains $5 price target.
2024-09-24 21:58